Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.

Chemotherapy - 1 Jan 2021

Menna Pierantonio, Salvatorelli Emanuela, Del Principe Maria Ilaria, Perrone Salvatore, Pagano Livio, Marchesi Francesco, Minotti Giorgio

Abstract excerpt

INTRODUCTION: Patients treated with midostaurin and chemotherapy are at risk of invasive fungal disease. Prophylactic posaconazole is recommended for these patients, but posaconazole strongly inhibits the CYP3A4 isozyme that metabolizes midostaurin. Posaconazole therefore introduces a risk of patient's overexposure to midostaurin. METHODS: Blood samples were obtained from 4 patients treated with midostaurin for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mycoses

Share to Staurosporine

Share to Triazoles

Source

Identifiers

PMID: 33677444
DOI: 10.1159/000513989

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.PMID 33677444Read ↗

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.Semantic proximity Read ↗

Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.Semantic proximity Read ↗

Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).Semantic proximity Read ↗

Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.Semantic proximity Read ↗

Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia.Semantic proximity Read ↗

Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.Semantic proximity Read ↗

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.Semantic proximity Read ↗

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.Semantic proximity Read ↗

Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol.Semantic proximity Read ↗

Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics.Semantic proximity Read ↗

Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.